Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Portfolio Pulse from Vandana Singh
Vivos Therapeutics has received FDA 510(k) clearance for its DNA appliance, designed to treat pediatric obstructive sleep apnea (OSA) and snoring. This approval allows Vivos to enter the pediatric market, potentially capturing significant market share. The device is non-invasive and effective, with clinical trials showing significant improvements in sleep-related symptoms. Vivos plans to quickly integrate this into its marketing model to scale revenue.
September 18, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics received FDA clearance for its DNA appliance to treat pediatric sleep apnea, marking a significant market opportunity. The device's effectiveness and non-invasive nature could lead to rapid revenue growth.
The FDA approval for Vivos' DNA appliance allows the company to enter the pediatric sleep apnea market, which is significant given the large number of affected children. The device's proven effectiveness and non-invasive nature make it a strong alternative to existing treatments. This regulatory milestone is likely to boost investor confidence and drive stock prices up, as evidenced by the immediate 37.80% increase in VVOS stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100